Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


«12...7891011121314151617...3940»
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date:  Once Weekly GLP-1 in Persons With Spinal Cord Injury (clinicaltrials.gov) -  Mar 14, 2023   
    P4,  N=5, Completed, 
    Unknown status --> Completed | N=30 --> 5 | Trial completion date: Dec 2021 --> Mar 2023
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Observational data, Journal, Real-world evidence, Real-world:  Once-Weekly Semaglutide Use in Type (Pubmed Central) -  Mar 9, 2023   
    P=N/A
    Individuals with T2D treated with OW semaglutide experienced significant and clinically relevant improvements in glycaemic control and BW from baseline. These results from a diverse real-world population in the Netherlands support the use of OW semaglutide in treating adults with T2D in routine clinical practice.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Trial Tokenization Accelerating Innovation in SEPRA  () -  Mar 9, 2023 - Abstract #ISPOR2023ISPOR_840;    
    P4
    Approximately half of the participants enrolled in SEPRA had available claims data and their baseline demographics were similar to the overall trial population. The use of this innovative approach within SEPRA provides an example for future research studies wherein multiple data sources are linked to evaluate patient outcomes through tokenization.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Utilization of Glucagon-like Peptide-1 Receptor Agonists in Canada () -  Mar 9, 2023 - Abstract #ISPOR2023ISPOR_778;    
    Formulary management strategies (prior authorization or prescriber audits) can promote the appropriate use of GLP-1 RAs. Future research in this field should assess if similar patterns are seen with private insurance, if non-T2DM GLP-1 RA use can be detected for individuals circumventing current funding criteria, and the effects of direct-to-consumer advertising on appropriate drug use.
  • ||||||||||  Saxenda (liraglutide 3 mg) / Novo Nordisk
    New trial, Inflammatory cell:  Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) -  Mar 6, 2023   
    P=N/A,  N=24, Not yet recruiting, 
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly
    Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States. (Pubmed Central) -  Mar 2, 2023   
    Once-weekly tirzepatide 10 mg was associated with higher cost and greater reduction in A1c and weight vs semaglutide. Tirzepatide 10 mg is cost-effective compared with semaglutide 1 mg if payers' willingness-to-pay threshold exceeds $2,247 for 1% reduction in A1c level and $237 for 1 kg weight loss.